CT/NG Testing Market

CT/NG Testing Market Size, Share, Growth Analysis, By Product(Assays & Kits, Instruments/Analyzers), By Testing Type(Lab Tests, PoC Tests), By Technology(Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction), By End User(Diagnostic Laboratories, Hospitals & Clinics), By Region(North America, US) - Industry Forecast 2024-2031

Report ID: UCMIG35H2254 | Region: Global | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

CT/NG Testing Market Insights

Market Overview:

The expected value of the global CT/NG testing market in terms of revenue was $1.7 billion in 2023, and it is anticipated to increase to $2.7 billion by 2028, rising at a CAGR of 8.6% between 2023 and 2028. Increasing finance and investments will fuel market expansion. The CT/NG testing market has growth potential thanks to government programs, funding initiatives, and other initiatives that support and promote innovation and development.

CT/NG Testing Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Biotechnology by segment aggregation, the contribution of the Biotechnology in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The CT/NG Testing Market is segmented by Product, Testing Type, Technology, End User, Region. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

CT/NG Testing Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Product the market is segmented as, Assays & Kits, Instruments/Analyzers
  • Based on Testing Type the market is segmented as, Lab Tests, PoC Tests
  • Based on Technology the market is segmented as, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
  • Based on End User the market is segmented as, Diagnostic Laboratories, Hospitals & Clinics, Other End Users
  • Based on Region the market is segmented as, North America, US, Canada, Europe, Germany, UK, France, Italy, Spain, Rest of Europe, Asia Pacific, China, Japan, India, Rest of Asia Pacific, Latin America, Middle East & Africa, Key Market Players, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Siemens Healthineers AG Danaher, Becton, Dickinson and Company

Regional Analysis:

CT/NG Testing Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

CT/NG Testing Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

CT/NG Testing Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on CT/NG Testing Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect CT/NG Testing Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key CT/NG Testing Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the CT/NG Testing Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • CT/NG testing market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of CT/NG infections and the growing investments and funding for R&D in CT/NG diagnosis.
  • On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent.
  • CT/NG testing Market Dynamics
  • DRIVER: Increasing investments and funding to drive market growth
  • Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the CT/NG testing market. These financial incentives and support systems enable companies to invest in research and development, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers are encouraged to push the boundaries of CT/NG testing, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine. For instance, in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) stated that it was collaborating with The Body Agency Collective (TBAC) and Visby Medical, Inc., to improve sexually transmitted infection (STI) diagnosis and treatment in observance of National STD Awareness Week. This project will utilize a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis.
  • RESTRAINT: High cost of instruments
  • The entire cost is increased by the variable costs of the required reagents, instruments and those set up by the suppliers. Maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space and administration) are extra costs as well. Only major hospitals and reference laboratories with healthy capital budgets may be able to afford the huge amount of diagnostic equipment. On the other hand, small laboratories, physicians’ offices, and private or individual practitioners encounter capital constraints and therefore, can find it difficult to afford a big or huge instruments and analyzer. Generally, a CT/NG testing kits and instruments can cost between USD 2,000 and USD 80,000. These, costly requirements might hinder the growth of the CT/NG (STI) testing market.
  • OPPORTUNITY: Growing opportunities in emerging countries
  • Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the CT/NG testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infections, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries. For example, according to the OECD, the purchasing power of the growing middle-class population is expected to increase to 65% by 2022 from 23% in 2009. This is expected to result in the increasing medical needs of the middle-class population, which will favor market growth. Moreover, as markets in the US and Europe mature, most players will shift their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of CT/NG testing (CT/NG testing).
  • CHALLENGE: Operational barriers and shortage of skills across major markets
  • Clinical laboratories are still developing in all; technicians must overcome practical obstacles to ensure efficient sample collection, storage, and transportation. To prevent cross-contamination and maintain efficient time management, laboratory areas must also be redesigned to conduct particular diagnostic procedures used for pathogen detection. This causes maintenance and operation of modern CT/NG devices, particularly those equipped to handle a single sample type, to significantly increase in cost.
  • Furthermore, clinical laboratories need to embrace cutting-edge technologies capable of quick sample diagnosis due to due to rapid mutation of micro-organisms and the rise in epidemic outbreak. However, the overall adoption of modern molecular diagnostics technologies has hampered, particularly in emerging economies, by the lack of experienced and technically educated laboratory staff.
  • Assays & kits segment accounted for the largest share of the CT/NG Testing Industry in 2022, by product
  • Based on product, the global CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The high share of this segment is attributed to its in-demand and continuous need for diagnosis and treatment. Due to recurrent purchasing it is a high cost product and thereby adds to the segment growth.
  • Lab tests segment accounted for the largest share in the CT/NG testing industry in 2022, by testing type
  • The global CT/NG testing market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the CT/NG testing market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases.
  • Lab tests are equipped with higher sensitivity and specificity compared to PoC tests. Having a controlled laboratory environment ensures more accurate and sensitive measurements, thereby reducing the chances of false-negative or false-positive results. Another advantage of lab tests is the ability to process a more number of samples simultaneously. Such factors are expected to fuel the growth of this segment.
  • North America accounted for the largest share of the CT/NG testing industry in 2022
  • The CT/NG testing market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the CT/NG testing industry. North America has been at the forefront of technological advancements in the field of diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the CT/NG testing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent CT/NG testing companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US).
  • Recent Developments in CT/NG Testing Industry
  • In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.
  • In May 2022, Hologic, Inc. (US) acquired Diagenode (US), a developer and manufacturer of molecular diagnostic assays and epigenetics products. This acquisition will further strengthen the company’s molecular diagnostics business by expanding its international capabilities and improving its regional time-to-market.
  • In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.
  • In September 2020, QIAGEN (Netherlands) Acquired NeuMoDx Molecular (US) to expand QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology
  • KEY MARKET SEGMENTS
  • By Product
  • Assays & Kits
  • Instruments/Analyzers
  • By Testing Type
  • Lab Tests
  • PoC Tests
  • By Technology
  • Isothermal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Other Technologies
  • By End User
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users
  • By Region
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa
  • Key Market Players
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG Danaher
  • Becton, Dickinson and Company

SkyQuest's Expertise:

The CT/NG Testing Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Product - Assays & Kits, Instruments/Analyzers
  • By Testing Type - Lab Tests, PoC Tests
  • By Technology - Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
  • By End User - Diagnostic Laboratories, Hospitals & Clinics, Other End Users
  • By Region - North America, US, Canada, Europe, Germany, UK, France, Italy, Spain, Rest of Europe, Asia Pacific, China, Japan, India, Rest of Asia Pacific, Latin America, Middle East & Africa, Key Market Players, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Siemens Healthineers AG Danaher, Becton, Dickinson and Company
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • CT/NG testing market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of CT/NG infections and the growing investments and funding for R&D in CT/NG diagnosis.
  • On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent.
  • CT/NG testing Market Dynamics
  • DRIVER: Increasing investments and funding to drive market growth
  • Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the CT/NG testing market. These financial incentives and support systems enable companies to invest in research and development, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers are encouraged to push the boundaries of CT/NG testing, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine. For instance, in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) stated that it was collaborating with The Body Agency Collective (TBAC) and Visby Medical, Inc., to improve sexually transmitted infection (STI) diagnosis and treatment in observance of National STD Awareness Week. This project will utilize a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis.
  • RESTRAINT: High cost of instruments
  • The entire cost is increased by the variable costs of the required reagents, instruments and those set up by the suppliers. Maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space and administration) are extra costs as well. Only major hospitals and reference laboratories with healthy capital budgets may be able to afford the huge amount of diagnostic equipment. On the other hand, small laboratories, physicians’ offices, and private or individual practitioners encounter capital constraints and therefore, can find it difficult to afford a big or huge instruments and analyzer. Generally, a CT/NG testing kits and instruments can cost between USD 2,000 and USD 80,000. These, costly requirements might hinder the growth of the CT/NG (STI) testing market.
  • OPPORTUNITY: Growing opportunities in emerging countries
  • Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the CT/NG testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infections, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries. For example, according to the OECD, the purchasing power of the growing middle-class population is expected to increase to 65% by 2022 from 23% in 2009. This is expected to result in the increasing medical needs of the middle-class population, which will favor market growth. Moreover, as markets in the US and Europe mature, most players will shift their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of CT/NG testing (CT/NG testing).
  • CHALLENGE: Operational barriers and shortage of skills across major markets
  • Clinical laboratories are still developing in all; technicians must overcome practical obstacles to ensure efficient sample collection, storage, and transportation. To prevent cross-contamination and maintain efficient time management, laboratory areas must also be redesigned to conduct particular diagnostic procedures used for pathogen detection. This causes maintenance and operation of modern CT/NG devices, particularly those equipped to handle a single sample type, to significantly increase in cost.
  • Furthermore, clinical laboratories need to embrace cutting-edge technologies capable of quick sample diagnosis due to due to rapid mutation of micro-organisms and the rise in epidemic outbreak. However, the overall adoption of modern molecular diagnostics technologies has hampered, particularly in emerging economies, by the lack of experienced and technically educated laboratory staff.
  • Assays & kits segment accounted for the largest share of the CT/NG Testing Industry in 2022, by product
  • Based on product, the global CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The high share of this segment is attributed to its in-demand and continuous need for diagnosis and treatment. Due to recurrent purchasing it is a high cost product and thereby adds to the segment growth.
  • Lab tests segment accounted for the largest share in the CT/NG testing industry in 2022, by testing type
  • The global CT/NG testing market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the CT/NG testing market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases.
  • Lab tests are equipped with higher sensitivity and specificity compared to PoC tests. Having a controlled laboratory environment ensures more accurate and sensitive measurements, thereby reducing the chances of false-negative or false-positive results. Another advantage of lab tests is the ability to process a more number of samples simultaneously. Such factors are expected to fuel the growth of this segment.
  • North America accounted for the largest share of the CT/NG testing industry in 2022
  • The CT/NG testing market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the CT/NG testing industry. North America has been at the forefront of technological advancements in the field of diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the CT/NG testing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent CT/NG testing companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US).
  • Recent Developments in CT/NG Testing Industry
  • In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.
  • In May 2022, Hologic, Inc. (US) acquired Diagenode (US), a developer and manufacturer of molecular diagnostic assays and epigenetics products. This acquisition will further strengthen the company’s molecular diagnostics business by expanding its international capabilities and improving its regional time-to-market.
  • In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.
  • In September 2020, QIAGEN (Netherlands) Acquired NeuMoDx Molecular (US) to expand QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology
  • KEY MARKET SEGMENTS
  • By Product
  • Assays & Kits
  • Instruments/Analyzers
  • By Testing Type
  • Lab Tests
  • PoC Tests
  • By Technology
  • Isothermal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Other Technologies
  • By End User
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users
  • By Region
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa
  • Key Market Players
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG Danaher
  • Becton, Dickinson and Company
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on CT/NG Testing Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on CT/NG Testing Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • CT/NG testing market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of CT/NG infections and the growing investments and funding for R&D in CT/NG diagnosis.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • CT/NG testing Market Dynamics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • DRIVER: Increasing investments and funding to drive market growth
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the CT/NG testing market. These financial incentives and support systems enable companies to invest in research and development, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers are encouraged to push the boundaries of CT/NG testing, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine. For instance, in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) stated that it was collaborating with The Body Agency Collective (TBAC) and Visby Medical, Inc., to improve sexually transmitted infection (STI) diagnosis and treatment in observance of National STD Awareness Week. This project will utilize a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • RESTRAINT: High cost of instruments
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The entire cost is increased by the variable costs of the required reagents, instruments and those set up by the suppliers. Maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space and administration) are extra costs as well. Only major hospitals and reference laboratories with healthy capital budgets may be able to afford the huge amount of diagnostic equipment. On the other hand, small laboratories, physicians’ offices, and private or individual practitioners encounter capital constraints and therefore, can find it difficult to afford a big or huge instruments and analyzer. Generally, a CT/NG testing kits and instruments can cost between USD 2,000 and USD 80,000. These, costly requirements might hinder the growth of the CT/NG (STI) testing market.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • OPPORTUNITY: Growing opportunities in emerging countries
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the CT/NG testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infections, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries. For example, according to the OECD, the purchasing power of the growing middle-class population is expected to increase to 65% by 2022 from 23% in 2009. This is expected to result in the increasing medical needs of the middle-class population, which will favor market growth. Moreover, as markets in the US and Europe mature, most players will shift their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of CT/NG testing (CT/NG testing).
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • CHALLENGE: Operational barriers and shortage of skills across major markets
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Clinical laboratories are still developing in all; technicians must overcome practical obstacles to ensure efficient sample collection, storage, and transportation. To prevent cross-contamination and maintain efficient time management, laboratory areas must also be redesigned to conduct particular diagnostic procedures used for pathogen detection. This causes maintenance and operation of modern CT/NG devices, particularly those equipped to handle a single sample type, to significantly increase in cost.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Furthermore, clinical laboratories need to embrace cutting-edge technologies capable of quick sample diagnosis due to due to rapid mutation of micro-organisms and the rise in epidemic outbreak. However, the overall adoption of modern molecular diagnostics technologies has hampered, particularly in emerging economies, by the lack of experienced and technically educated laboratory staff.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Assays & kits segment accounted for the largest share of the CT/NG Testing Industry in 2022, by product
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Based on product, the global CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The high share of this segment is attributed to its in-demand and continuous need for diagnosis and treatment. Due to recurrent purchasing it is a high cost product and thereby adds to the segment growth.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Lab tests segment accounted for the largest share in the CT/NG testing industry in 2022, by testing type
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The global CT/NG testing market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the CT/NG testing market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Lab tests are equipped with higher sensitivity and specificity compared to PoC tests. Having a controlled laboratory environment ensures more accurate and sensitive measurements, thereby reducing the chances of false-negative or false-positive results. Another advantage of lab tests is the ability to process a more number of samples simultaneously. Such factors are expected to fuel the growth of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America accounted for the largest share of the CT/NG testing industry in 2022
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The CT/NG testing market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the CT/NG testing industry. North America has been at the forefront of technological advancements in the field of diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the CT/NG testing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent CT/NG testing companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US).
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Recent Developments in CT/NG Testing Industry
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In May 2022, Hologic, Inc. (US) acquired Diagenode (US), a developer and manufacturer of molecular diagnostic assays and epigenetics products. This acquisition will further strengthen the company’s molecular diagnostics business by expanding its international capabilities and improving its regional time-to-market.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In September 2020, QIAGEN (Netherlands) Acquired NeuMoDx Molecular (US) to expand QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Product
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Assays & Kits
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Instruments/Analyzers
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Testing Type
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Lab Tests
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • PoC Tests
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Technology
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Isothermal Nucleic Acid Amplification Technology
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Polymerase Chain Reaction
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Immunodiagnostics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Other Technologies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By End User
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Diagnostic Laboratories
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospitals & Clinics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Other End Users
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Region
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • US
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Canada
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Germany
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • UK
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • France
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Italy
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Spain
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Rest of Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • China
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Japan
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • India
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Rest of Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Middle East & Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Key Market Players
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • F. Hoffmann-La Roche Ltd.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hologic, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Thermo Fisher Scientific Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Abbott Laboratories
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bio-Rad Laboratories, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Siemens Healthineers AG Danaher
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Becton, Dickinson and Company
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the CT/NG Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the CT/NG Testing Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the CT/NG Testing Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the CT/NG Testing Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The market for CT/NG Testing was estimated to be valued at US$ XX Mn in 2021.

The CT/NG Testing Market is estimated to grow at a CAGR of XX% by 2028.

The CT/NG Testing Market is segmented on the basis of Product, Testing Type, Technology, End User, Region.

Based on region, the CT/NG Testing Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the CT/NG Testing Market are CT/NG testing market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of CT/NG infections and the growing investments and funding for R&D in CT/NG diagnosis. , On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent. , CT/NG testing Market Dynamics , DRIVER: Increasing investments and funding to drive market growth , Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the CT/NG testing market. These financial incentives and support systems enable companies to invest in research and development, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers are encouraged to push the boundaries of CT/NG testing, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine. For instance, in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) stated that it was collaborating with The Body Agency Collective (TBAC) and Visby Medical, Inc., to improve sexually transmitted infection (STI) diagnosis and treatment in observance of National STD Awareness Week. This project will utilize a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis. , RESTRAINT: High cost of instruments , The entire cost is increased by the variable costs of the required reagents, instruments and those set up by the suppliers. Maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space and administration) are extra costs as well. Only major hospitals and reference laboratories with healthy capital budgets may be able to afford the huge amount of diagnostic equipment. On the other hand, small laboratories, physicians’ offices, and private or individual practitioners encounter capital constraints and therefore, can find it difficult to afford a big or huge instruments and analyzer. Generally, a CT/NG testing kits and instruments can cost between USD 2,000 and USD 80,000. These, costly requirements might hinder the growth of the CT/NG (STI) testing market. , OPPORTUNITY: Growing opportunities in emerging countries , Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the CT/NG testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infections, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries. For example, according to the OECD, the purchasing power of the growing middle-class population is expected to increase to 65% by 2022 from 23% in 2009. This is expected to result in the increasing medical needs of the middle-class population, which will favor market growth. Moreover, as markets in the US and Europe mature, most players will shift their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of CT/NG testing (CT/NG testing). , CHALLENGE: Operational barriers and shortage of skills across major markets , Clinical laboratories are still developing in all; technicians must overcome practical obstacles to ensure efficient sample collection, storage, and transportation. To prevent cross-contamination and maintain efficient time management, laboratory areas must also be redesigned to conduct particular diagnostic procedures used for pathogen detection. This causes maintenance and operation of modern CT/NG devices, particularly those equipped to handle a single sample type, to significantly increase in cost. , Furthermore, clinical laboratories need to embrace cutting-edge technologies capable of quick sample diagnosis due to due to rapid mutation of micro-organisms and the rise in epidemic outbreak. However, the overall adoption of modern molecular diagnostics technologies has hampered, particularly in emerging economies, by the lack of experienced and technically educated laboratory staff. , Assays & kits segment accounted for the largest share of the CT/NG Testing Industry in 2022, by product , Based on product, the CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The high share of this segment is attributed to its in-demand and continuous need for diagnosis and treatment. Due to recurrent purchasing it is a high cost product and thereby adds to the segment growth. , Lab tests segment accounted for the largest share in the CT/NG testing industry in 2022, by testing type , The CT/NG testing market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the CT/NG testing market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases. , Lab tests are equipped with higher sensitivity and specificity compared to PoC tests. Having a controlled laboratory environment ensures more accurate and sensitive measurements, thereby reducing the chances of false-negative or false-positive results. Another advantage of lab tests is the ability to process a more number of samples simultaneously. Such factors are expected to fuel the growth of this segment. , North America accounted for the largest share of the CT/NG testing industry in 2022 , The CT/NG testing market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the CT/NG testing industry. North America has been at the forefront of technological advancements in the field of diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the CT/NG testing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent CT/NG testing companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US). , Recent Developments in CT/NG Testing Industry , In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases. , In May 2022, Hologic, Inc. (US) acquired Diagenode (US), a developer and manufacturer of molecular diagnostic assays and epigenetics products. This acquisition will further strengthen the company’s molecular diagnostics business by expanding its international capabilities and improving its regional time-to-market. , In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing. , In September 2020, QIAGEN (Netherlands) Acquired NeuMoDx Molecular (US) to expand QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology , KEY MARKET SEGMENTS , By Product , Assays & Kits , Instruments/Analyzers , By Testing Type , Lab Tests , PoC Tests , By Technology , Isothermal Nucleic Acid Amplification Technology , Polymerase Chain Reaction , Immunodiagnostics , Other Technologies , By End User , Diagnostic Laboratories , Hospitals & Clinics , Other End Users , By Region , North America , US , Canada , Europe , Germany , UK , France , Italy , Spain , Rest of Europe , Asia Pacific , China , Japan , India , Rest of Asia Pacific , Latin America , Middle East & Africa , Key Market Players , F. Hoffmann-La Roche Ltd. , Hologic, Inc. , Thermo Fisher Scientific Inc. , Abbott Laboratories , Bio-Rad Laboratories, Inc. , Siemens Healthineers AG Danaher , Becton, Dickinson and Company.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Flow Cytometry Market
Buy Now GET FREE SAMPLE
Mutation Detection Kits In Genome Editing Market
Buy Now GET FREE SAMPLE
Aquafeed Additives Market
Buy Now GET FREE SAMPLE
Type 1 Diabetes Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

CT/NG Testing Market

Product ID: UCMIG35H2254

$5,300
BUY NOW GET FREE SAMPLE